Abstract
Background
Role of cytokines as well as matrix metalloproteinases (MMPs) is well defined in various central nervous system inflammatory diseases. However, the role of these cytokines and MMPs in acute transverse myelitis is inadequately studied.
Materials and methods
Patients with acute transverse myelitis, fulfilling the inclusion and exclusion criteria defined by Transverse Myelitis Consortium Working Group, were enrolled along with age and sex matched controls. A detailed clinical evaluation and magnetic resonance imaging of patients was done. Cerebrospinal fluid (CSF) samples both from patients and controls were collected. CSF samples were analyzed for cytokines [interleukin (IL)-6, IL-8, IL-10 and IL-17)] and matrix metalloproteinases (MMP-2, MMP-9). Patients were followed up for 3 months. Disability was assessed using modified Barthel index (MBI).
Results
CSF levels of all cytokines IL-6, IL-8, IL-10, MMP-2 and MMP-9, except IL-17, were significantly higher in patients with acute transverse myelitis (p < 0.001). CSF IL-6 and IL-8 were significantly associated with severity of the disease (MBI ≤ 12). After 3 months, quadriparesis (p = 0.001, odd’s ratio 19.5, 95 % CI 2.34–62.39) and long-segment myelitis (p = 0.035, odd’s ratio 4.37, 95 % CI 1.17–5.95) were significantly associated with poor outcome. Among cytokines and MMPs, IL-6 levels at baseline correlated significantly with the MBI at 3 months (Spearmen’s ρ = −0.335, p = 0.01).
Conclusion
In conclusion, both anti-inflammatory and pro-inflammatory cytokines, MMP-2, and MMP-9 are elevated in the acute phase of transverse myelitis. Possibly, IL-6 plays a role in determining the disability.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59:499–505.
Kaplin AI, Krishnan C, Deshpande DM, Pardo CA, Kerr DA. Diagnosis and management of acute myelopathies. Neurologist. 2005;11:2–18.
Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, Kerr DA. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004;9:1483–99.
Pandit L. Transverse myelitis spectrum disorders. Neurol India. 2009;57:126–33.
Cree BAC. Acute inflammatory myelopathies. Handb Clin Neurol. 2014;122:613–67.
Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, Taniguchi J, Kuwabara S. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16:1443–52.
Wullschleger A, Kapina V, Molnarfi N, Courvoisier DS, Seebach JD, Santiago-Raber ML, Hochstrasser DF, Lalive PH. Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. PLoS ONE. 2013;8:e72399.
Romanic AM, Madri JA. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 1994;4:145–56.
Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002;39:279–91.
Tasaki A, Shimizu F, Sano Y, Fujisawa M, Takahashi T, Haruki H, Abe M, Koga M, Kanda T. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2014;85:419–30.
Bruna J, Martínez-Yélamos S, Martínez-Yélamos A, Rubio F, Arbizu T. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler. 2006;12:169–73.
Hofer MJ, Campbell IL. Immunoinflammatory diseases of the central nervous system—the tale of two cytokines. Br J Pharmacol. 2015. doi:10.1111/bph.13175.
Linhares UC, Schiavoni PB, Barros PO, Kasahara TM, Teixeira B, Ferreira TB, Alvarenga R, Hygino J, Vieira MM, Bittencourt VC, Andrade RM, Andrade AF, Bento CA. The ex vivo production of IL-6 and IL-21 by CD4 + T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol. 2013;33:179–89.
Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Investig. 2005;115:2731–41.
Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, Miyake S, Aranami T, Yamamura T. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82:1302–6.
Hosokawa T, Nakajima H, Doi Y, Sugino M, Kimura F, Hanafusa T, Takahashi T. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood–brain barrier. J Neuroimmunol. 2011;236:81–6.
Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, Rosenberg GA. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic’s neuromyelitis optica. Brain. 2001;124:493–8.
Graber JJ, Allie SR, Mullen KM, Jones MV, Wang T, Krishnan C, et al. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol. 2008;196:124–32.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible Editor: Ji Zhang.
Rights and permissions
About this article
Cite this article
Dixit, P., Garg, R.K., Malhotra, H.S. et al. Cytokines and matrix metalloproteinases in the cerebrospinal fluid of patients with acute transverse myelitis: an outcome analysis. Inflamm. Res. 65, 125–132 (2016). https://doi.org/10.1007/s00011-015-0896-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-015-0896-8